We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+8.96%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$6.93B
AUM Growth
+$1.84B
Cap. Flow
+$1.42B
Cap. Flow %
20.44%
Top 10 Hldgs %
40.16%
Holding
121
New
33
Increased
24
Reduced
21
Closed
24

Top Buys

Rank Stock Value
1
FRX
FOREST LABORATORIES INC
FRX
+$628M
2
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$165M
3
QCOR
QUESTCOR PHARMA INC
QCOR
+$159M
4
HSH
HILLSHIRE BRANDS CO
HSH
+$138M
5
AGN
Allergan Inc
AGN
+$95.4M

Top Sells

Rank Stock Value
1
TWC
TIME WARNER CABLE INC NEW COM STK
TWC
+$251M
2
DG icon
Dollar General
DG
+$180M
3
CHTR icon
Charter Communications
CHTR
+$99.8M
4
DIS icon
Walt Disney
DIS
+$97.1M
5
SIRI icon
SiriusXM
SIRI
+$67.6M

Sector Composition

Rank Sector Weight
1 Healthcare 20.33%
2 Consumer Discretionary 12.11%
3 Real Estate 9.7%
4 Consumer Staples 9.64%
5 Communication Services 9.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCIP
76
DELISTED
OCI Partners LP
OCIP
$4.22M 0.06%
198,592
-301,408
-60% -$6.39M
OIS icon
77
Oil States International
OIS
$522M
$3.27M 0.05%
+51,050
New +$3M
KIN
78
DELISTED
Kindred Biosciences, Inc.
KIN
$3.26M 0.05%
+175,000
New +$2.97M
EIGR
79
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$3.2M 0.05%
444
-160
-26% -$801K
TPH
80
DELISTED
Tri Pointe Homes
TPH
$2.52M 0.04%
+160,000
New +$2.59M
CNL
81
DELISTED
CLECO CRP (HOLDING CO)
CNL
$2.29M 0.03%
+38,894
New +$2.03M
GRFS
82
Grifois
GRFS
$5.44B
$2.26M 0.03%
102,764
-2,028,090
-95% -$42.4M
ALDR
83
DELISTED
Alder Biopharmaceuticals
ALDR
$2.01M 0.03%
+100,000
New +$1.41M
ARQL
84
DELISTED
Arqule Inc
ARQL
$1.95M 0.03%
1,258,732
– –
ACAD icon
85
Acadia Pharmaceuticals
ACAD
$5.08B
$1.58M 0.02%
70,000
– –
FATE icon
86
Fate Therapeutics
FATE
$279M
$1.57M 0.02%
248,102
-26,898
-10% -$189K
EGRX
87
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$1.43M 0.02%
100,000
– –
STML
88
DELISTED
Stemline Therapeutics, Inc.
STML
$1.39M 0.02%
95,000
– –
CORI
89
DELISTED
Corium International, Inc.
CORI
$971K 0.01%
+125,000
New +$942K
QURE icon
90
uniQure
QURE
$3.36B
$680K 0.01%
50,000
– –
IBP icon
91
Installed Building Products
IBP
$6.56B
$593K 0.01%
48,398
-130,426
-73% -$1.74M
NGNE icon
92
Neurogene
NGNE
$773M
$451K 0.01%
2,405
-95
-4% -$18.3K
ANIP icon
93
ANI Pharmaceuticals
ANIP
$1.73B
– –
-30,000
Closed -$941K
CPF icon
94
Central Pacific Financial
CPF
$964M
– –
-306,042
Closed -$6.18M
CYH icon
95
Community Health Systems
CYH
$424M
– –
-302,500
Closed -$9.79M
DG icon
96
Dollar General
DG
$27.2B
– –
-3,245,000
Closed -$180M
DIS icon
97
Walt Disney
DIS
$186B
– –
-1,212,500
Closed -$97.1M
FBIO icon
98
Fortress Biotech
FBIO
$95.7M
– –
-3,933
Closed -$117K
IRM icon
99
Iron Mountain
IRM
$36.3B
– –
-968,390
Closed -$24.7M
MCK icon
100
McKesson
MCK
$100B
– –
-86,500
Closed -$15.3M
1 2 3
4
5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q2 2014 Portfolio in Review

As of Q2 2014, Thomas Steyer held 121 positions worth $6.93B, up 36% from $5.09B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Thomas Steyer deployed $1.42B of net new capital in Q2 2014, opening 33 new positions and adding to 24 existing holdings. Its largest new stake was COVIDIEN PLC COM SHS NEW (IRELAND): 2,200,000 shares worth $198M.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 7.4% a quarter earlier, followed by Consumer Discretionary and Real Estate.

On the sell side, the largest reduction was Charter Communications, an estimated $99.8M trimmed.

  • Thomas Steyer's largest Q2 2014 buy was COVIDIEN PLC COM SHS NEW (IRELAND): 2,200,000 shares worth $198M.
  • Thomas Steyer added most to FOREST LABORATORIES INC in Q2 2014, an estimated $628M increase.
  • Thomas Steyer's biggest Q2 2014 reduction was Charter Communications, cutting an estimated $99.8M.
  • Thomas Steyer fully exited TIME WARNER CABLE INC NEW COM STK in Q2 2014, selling an estimated $251M.
  • Thomas Steyer's ten largest holdings make up 40% of its $6.93B portfolio in Q2 2014.
  • Thomas Steyer opened 33 new positions and closed 24 in Q2 2014.
  • Thomas Steyer's portfolio value rose 36% quarter-over-quarter to $6.93B.

Based on Farallon Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.